ATH434 for Multiple System Atrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ATH434 to determine its safety and effectiveness for people with Multiple System Atrophy (MSA), a condition affecting movement, balance, and automatic body functions like blood pressure and bladder control. The trial focuses on individuals experiencing symptoms such as dizziness when standing (orthostatic hypotension), bladder issues, and coordination problems (ataxia). Participants must also have specific test results indicating MSA. The study aims to explore whether ATH434 can better manage these symptoms. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of people.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ATH434 is likely to be safe for humans?
Research has shown that ATH434 is generally safe for people with Multiple System Atrophy (MSA). Studies have found it does not cause serious side effects. The number of unwanted side effects is similar to those in placebo groups, indicating no major safety issues. This suggests ATH434 is safe for humans based on current evidence.12345
Why do researchers think this study treatment might be promising?
Most treatments for Multiple System Atrophy (MSA) focus on managing symptoms, like using medications for movement issues or blood pressure problems. But ATH434 works differently, targeting the underlying cause of brain cell damage. Researchers are excited about ATH434 because it specifically reduces the buildup of a protein called alpha-synuclein, which is thought to contribute to the progression of MSA. By addressing this root cause, ATH434 has the potential to slow down disease progression rather than just alleviate symptoms.
What evidence suggests that ATH434 might be an effective treatment for Multiple System Atrophy?
Research has shown that ATH434, the investigational treatment in this trial, may help treat Multiple System Atrophy (MSA). Recent studies found that ATH434 slowed the shrinking of brain areas affected by MSA. Patients taking ATH434 demonstrated noticeable improvement in their symptoms compared to those on a placebo. The treatment positively affected key indicators of the disease's presence or severity. These findings suggest that ATH434 could be a helpful option for people with MSA.12367
Are You a Good Fit for This Trial?
This trial is for individuals with Multiple System Atrophy (MSA), showing symptoms like parkinsonism, low blood pressure upon standing, bladder issues, ataxia or abnormal muscle coordination, and certain signs on a neurological exam. They must have MSA biomarkers in their body fluids and MRI scans. People can't join if they can't swallow pills, attend visits, have brain structure issues on MRI, unstable health conditions or other significant neurological disorders.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ATH434 to assess safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ATH434
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alterity Therapeutics
Lead Sponsor